Prostate cancer screening
1 / 23

Prostate cancer screening - PowerPoint PPT Presentation

  • Updated On :

Prostate cancer screening. Dr J P McMenamin. Prostate cancer. An important health problem in NZ. Approx 500 men die of prostate cancer every year. 13% male cancer deaths (3 rd most common after lung and bowel). Prostate cancer. 75% new diagnoses 70+ years Estimated lifetime risk of:

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Prostate cancer screening' - medwin

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Prostate cancer screening l.jpg

Prostate cancer screening

Dr J P McMenamin

Prostate cancer l.jpg
Prostate cancer

  • An important health problem in NZ.

  • Approx 500 men die of prostate cancer every year.

  • 13% male cancer deaths

  • (3rd most common after lung and bowel)

Prostate cancer3 l.jpg
Prostate cancer

  • 75% new diagnoses 70+ years

  • Estimated lifetime risk of:

    diagnosis = about 16%

    prostate cancer death 3% to 4%

  • Most common in older men

  • Most men with prostate cancer survive

Current practice l.jpg
Current practice

  • Many NZ GPs are screening

  • Opinions and practice are mixed

  • Mostly opportunistic and selective

  • Mostly using DRE/PSA

  • Tendency to investigation of borderline abnormal results

  • Some medical opinions and Prostate Support Groups advocate screening

Major risk factors l.jpg
Major Risk factors

  • Age

    (45% over 70yrs, 30% over 80yrs)

  • Ethnicity

    (African American ethnicity a risk,

    Maori incidence rising)

  • Family history

    ( up to x 2 for one, x 5 – 11 for more affected 1st degree relatives)

Prostate cancer screening tests l.jpg
Prostate cancer screening tests

  • DRE generally reported to perform poorly (PPV 6 – 30%)

  • TRUS generally considered a diagnostic test (PPV 5-9 %)

  • PSA considered most hopeful though unproven screening test

  • (PPV 28-35%)

Methods to improve psa detection of prostate cancer l.jpg
Methods to improve PSA detection of prostate cancer tests

  • High levels of complexed PSA, low levels of percent free PSA (free/total) associated prostate cancer

  • May be of most help in “grey zone”

    ( PSA 4 – 10)

  • No definitive evidence of improved screening outcomes compared with total PSA levels

Psa density l.jpg
PSA density tests

  • PSA density defined as serum PSA divided by gland volume

  • No definitive evidence of benefit as screening test

Psa velocity l.jpg
PSA Velocity tests

  • Serial increases in PSA may be associated with prostate cancer

  • Value as screening test remains unclear

Psa cut off values l.jpg
PSA cut-off values tests

  • Usual screening cut-off is 4.0ng/ml

  • Reducing cut-off improves detection rate (sensitivity) but results in more biopsies (reduces specificty)

  • Age adjustment remains unclear

    (lower cut-off younger men = more biopsies, higher cut-off older men = more cancers missed)

The case for screening a partial perspective l.jpg
The case for screening: a partial perspective tests

  • screening detects prostate cancer in a significant number of asymptomatic men.

  • A high proportion of cancers detected by screening are clinically localized at the time of diagnosis (screening has been shown to shift cancer detection to earlier stage)

  • Clinical outcomes after surgery for localized prostate cancer are known to be better

Regional mortality reductions l.jpg
Regional mortality reductions tests

  • PSA screening is associated with reduced mortality in a number of reports

The case against prostate cancer screening the rest of the argument l.jpg
The Case against tests Prostate Cancer Screening: the rest of the argument

  • Prostate cancer mortality rates declined relatively early after the initiation of widespread screening

  • it is unlikely that screening has as yet contributed in a major way to the decline

  • It is more likely that the mortality reduction is a consequence of better prostate cancer management or improved treatment modalities.

The case against prostate cancer screening the rest of the argument14 l.jpg
The Case against tests Prostate Cancer Screening: the rest of the argument

Most deaths (over 60%) occur in men 75 years of age and older

(a reduction in all-cause mortality, resulting in an actual increase in life expectancy, will be difficult to accomplish in this age group)

Natural history not well defined l.jpg
Natural history not well defined tests

  • The natural history of prostate cancer has not been well defined, and there is great variation in the aggressiveness of different tumours

  • bias toward screening detection of biologically indolent tumours, which are associated with a good prognosis, rather than detection of aggressive tumours with a poor prognosis.

Waiting for the evidence l.jpg
Waiting for the evidence tests

  • No definitive evidence of a benefit from screening yet

  • No definitive evidence of a mortality benefit from intervention

    (RCT has shown reduction in disease-specific but not all-cause mortality)

To screen or not to screen l.jpg
To screen tests or not to screen

PSA results in the detection of cancers at an early stage.

Treatment of early stage cancers has better disease outcomes

To screen or not to screen18 l.jpg
To screen tests or not to screen

But the fact that a cancer can be detected earlier in its natural history is no guarantee that benefit will follow

Screening for prostate cancer can substantially impair the quality of life of those with detected and treated cancer, that would not otherwise have reduced life expectancy.

Post screening complications l.jpg
Post-screening complications tests

  • Biopsy complications

    (infection 1%, bleeding 50%)

  • 2 year post-prostatectomy

    - Some degree incontinence 38%

    - Sexual dysfunction 50% - 60%

Conclusion l.jpg
Conclusion tests

“Decisions on the introduction of population-based screening for prostate cancer cannot be made before RCTs have been completed.”

The International Prostate Screening Trial

Evaluation Group.

2 international rcts l.jpg
2 international RCTs tests

  • European Randomized Screening for Prostate Cancer

  • Prostate, Lung, Colorectal and Ovarian (PCLO) Cancer Screening Trial

Slide22 l.jpg

Conclusion23 l.jpg
Conclusion tests

  • Evidence does not support active screening

  • Men requesting screening require information

  • Information needs to be up to date and readily available

  • NHC has published report and information resource